Vol 73, Supp. VI (2015)
Reviews
Published online: 2015-11-25

open access

Page views 406
Article views/downloads 851
Get Citation

Connect on Social Media

Connect on Social Media

XANTUS, a prospective, observational study of patients treated with rivaroxaban for stroke prevention in atrial fibrillation

Marek Postuła, Dariusz Kosior

Abstract

XANTUS is the first large, international prospective study to describe rivaroxaban use in a broad patient population with non-valvular atrial fibrillation. Out of 6784 patients, over 96% patients receiving rivaroxaban did not experience any of the outcomes of stroke/systemic embolism, treatment-emergent major bleeding or all-cause death. In XANTUS, rivaroxaban demonstrated low rates of stroke/ systemic embolism and major bleeding, including intracranial and gastrointestinal bleeding. Treatment persistence and patient satisfaction were high, namely 80% of patients remained on rivaroxaban and 75% reported they were satisfied with their treatment at one year.

Article available in PDF format

View PDF (Polish) Download PDF file



Polish Heart Journal (Kardiologia Polska)